Will Wave Life Sciences submit an NDA for WVE-N531 (DMD) to the FDA by year-end 2026?
Current Prediction
Why This Question Matters
WVE-N531 NDA submission for DMD was flagged by the Regulatory Reader as a pipeline breadth validation. Successful submission in 2026 would demonstrate execution beyond the headline obesity and AATD programs. Delay or refusal would narrow the perceived pipeline value.
Prediction Distribution
Individual Predictions(9 runs)
Management guidance and established pathway favor submission, but delays are common obstacles. Management guided 2026 submission provides partial support, but nda prep is complex creates counterweight. Probability: 0.7.
Management guidance and established pathway favor submission, but delays are common obstacles. Management guided 2026 submission provides partial support, but nda prep is complex creates counterweight. Probability: 0.57.
Management guidance and established pathway favor submission, but delays are common obstacles. Management guided 2026 submission provides partial support, but nda prep is complex creates counterweight. Probability: 0.57.
Base rate evidence: nda prep is complex. Partial offset from management guided 2026 submission. Management guidance and established pathway favor submission, but delays are common obstacles. Probability: 0.58.
Base rate evidence: nda prep is complex. Partial offset from management guided 2026 submission. Management guidance and established pathway favor submission, but delays are common obstacles. Probability: 0.48.
Base rate evidence: nda prep is complex. Partial offset from management guided 2026 submission. Management guidance and established pathway favor submission, but delays are common obstacles. Probability: 0.59.
Management guidance and established pathway favor submission, but delays are common obstacles. Balance of evidence suggests 0.48 probability. Primary support: management guided 2026 submission. Main counterargument: nda prep is complex.
Management guidance and established pathway favor submission, but delays are common obstacles. Balance of evidence suggests 0.62 probability. Primary support: management guided 2026 submission. Main counterargument: nda prep is complex.
Management guidance and established pathway favor submission, but delays are common obstacles. Balance of evidence suggests 0.56 probability. Primary support: management guided 2026 submission. Main counterargument: nda prep is complex.
Resolution Criteria
Resolves YES if Wave files an NDA or BLA for WVE-N531 with the FDA by December 31, 2026. Resolves NO if no submission is made by that date.
Resolution Source
Wave Life Sciences press releases, SEC filings, or FDA PDUFA listings
Source Trigger
WVE-N531 NDA submission planned for 2026; refuse-to-file or CRL would narrow perceived pipeline value
Full multi-lens equity analysis